Trial abstract · §3
SEMAX-RU-COGNITIVE — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Cognitive performance indices | Registered in the Russian Federation on a national evidence base the Institute has not been able to retrieve in full. No trial meeting the Institute’s inclusion criteria has been identified | Not rated |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Semax from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nasal irritation | — | — | Reported with intranasal use |
| No serious adverse events reported | — | — | In the available Russian studies, though adverse-event ascertainment methodology is not described to a standard permitting assessment |
Compound Evidence Institute · CEI-TR-0124/3 · https://compoundevidence.com/trials/semax-ru-cognitive/results/ · retrieved 30 July 2026